Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

Study identifier:D822EC00001

ClinicalTrials.gov identifier:NCT05665374

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

General Use-Results Study of Calquence capsules 100 mg in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)

Medical condition

Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

67

Study type

Observational

Age

n/a - n/a

Date

Study Start Date: 19 Jun 2023
Estimated Primary Completion Date: 11 May 2026
Estimated Study Completion Date: 11 May 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria